Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Ovarian Cancer treatment details. Chemotherapy. MD Anderson Cancer Center, University of Texas, Houston, TX, United States



Survival: 17.8 months
   
Toxicity Grade: 4
   
Treatments: Chemotherapy
   
Drugs:
Country: United States
   
City/State/Province: Houston, TX
   
Hospital: MD Anderson Cancer Center, University of Texas
   
Journal: Link
   
Date: 3/2010

Description:
Patients:
This phase 2 study involved 39 women with platinum refractory or resistant ovarian cancer. The median age was 54.5 years, with a range of 34.8-75.4.

Treatment:
Patients received a combination of two chemotherapeutic agents, canfosfamide (also known as TELCYTA or TLK286) and pegylated liposomal doxorubicin.

Toxicity:
The highest toxicity level observed in this study was Grade 4, mostly consisting of neutropenia. Other adverse events observed at a level less that 4 included nausea, fatigue, hair loss, and stomatitis (inflammation of the mouth).

Results:
The median overall survival reported in this study was 17.8 months. The reported median progression-free survival was 6 months.

Support:
Several of the authors are employed by Telik, Inc, the makers of canfosfamide.

Correspondence: Dr. Gail L. Brown

E-mail to a Friend Email Physician More Information